Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), and is being investigated for the treatment of psoriasis. |
There are currently no adequate or well-controlled studies of tofacitinib or any disease-modifying antirheumatic drug in pregnant women. |
Pregnancy outcomes reported in the tofacitinib RA and psoriasis safety databases appear similar to those observed in the general population and in patients treated with biologic therapies for inflammatory diseases. |